McLellan James L, Sausman William, Reers Ashley B, Bunnik Evelien M, Hanson Kirsten K
Department of Molecular Microbiology and Immunology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX, USA.
Department of Microbiology, Immunology, and Molecular Genetics, Long School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
bioRxiv. 2023 Jul 5:2023.07.05.547872. doi: 10.1101/2023.07.05.547872.
parasite resistance to existing antimalarial drugs poses a devastating threat to the lives of many who depend on their efficacy. New antimalarial drugs and novel drug targets are in critical need, along with novel assays to accelerate their identification. Given the essentiality of protein synthesis throughout the complex parasite lifecycle, translation inhibitors are a promising drug class, capable of targeting the disease-causing blood stage of infection, as well as the asymptomatic liver stage, a crucial target for prophylaxis. To identify compounds capable of inhibiting liver stage parasite translation, we developed an assay to visualize and quantify translation in the HepG2 infection model. After labeling infected monolayers with o-propargyl puromycin (OPP), a functionalized analog of puromycin permitting subsequent bioorthogonal addition of a fluorophore to each OPP-terminated nascent polypetide, we use automated confocal feedback microscopy followed by batch image segmentation and feature extraction to visualize and quantify the nascent proteome in individual liver stage parasites and host cells simultaneously. After validation, we demonstrate specific, concentration-dependent liver stage translation inhibition by both parasite-selective and pan-eukaryotic active compounds, and further show that acute pre-treatment and competition modes of the OPP assay can distinguish between direct and indirect translation inhibitors. We identify a Malaria Box compound, MMV019266, as a direct translation inhibitor in liver stages and confirm this potential mode of action in asexual blood stages.
寄生虫对现有抗疟药物产生耐药性,这对许多依赖这些药物疗效的人的生命构成了毁灭性威胁。迫切需要新的抗疟药物、新的药物靶点以及能够加速其鉴定的新检测方法。鉴于蛋白质合成在复杂的寄生虫生命周期中至关重要,翻译抑制剂是一类很有前景的药物,能够靶向致病的血液感染阶段以及无症状的肝脏阶段,而肝脏阶段是预防的关键靶点。为了鉴定能够抑制肝脏阶段寄生虫翻译的化合物,我们开发了一种检测方法,用于在HepG2感染模型中可视化和定量翻译过程。在用嘌呤霉素的功能化类似物邻炔丙基嘌呤霉素(OPP)标记感染的单层细胞后,这种类似物允许随后将荧光团生物正交添加到每个以OPP结尾的新生多肽上,我们使用自动共聚焦反馈显微镜,然后进行批量图像分割和特征提取,以同时可视化和定量单个肝脏阶段寄生虫和宿主细胞中的新生蛋白质组。经过验证,我们证明了寄生虫选择性和泛真核活性化合物对肝脏阶段翻译具有特异性的浓度依赖性抑制作用,并进一步表明OPP检测的急性预处理和竞争模式可以区分直接和间接翻译抑制剂。我们鉴定出一种疟疾盒化合物MMV019266,它在肝脏阶段是一种直接翻译抑制剂,并在无性血液阶段证实了这种潜在的作用模式。